STOCK TITAN

[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Gilead Sciences (GILD) disclosed an insider transaction by Chief Commercial Officer Johanna Mercier. On 10/15/2025, she sold 3,000 shares of common stock at $118.08 per share (transaction code S). After the sale, she beneficially owned 110,193 shares, held directly.

The filing states the trade was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Gilead Sciences (GILD) ha divulgato una operazione insider da parte della Chief Commercial Officer Johanna Mercier. Il 15/10/2025 ha venduto 3.000 azioni comuni a 118,08$ per azione (codice di transazione S). Dopo la vendita possedeva direttamente 110.193 azioni.

La dichiarazione indica che l'operazione è stata effettuata ai sensi di un piano di trading Rule 10b5-1 adottato il 20 febbraio 2025.

Gilead Sciences (GILD) divulgó una operación de insider por parte de la Directora Comercial Johanna Mercier. El 15/10/2025 vendió 3,000 acciones comunes a 118,08 dólares por acción (código de transacción S). Después de la venta, poseía directamente 110,193 acciones.

La declaración indica que la operación se realizó conforme a un plan de trading Rule 10b5-1 adoptado el 20 de febrero de 2025.

길리어드 사이언스(GILD) 최고 상무 이사인 조하나 메르시에가 내부자 거래를 공시했습니다. 2025년 10월 15일, 보통주 3,000주를 주당 118.08달러에 매도했습니다 (거래 코드 S). 매도 후 그녀는 직접 110,193주를 보유하게 되었습니다.

해당 공시는 거래가 2025년 2월 20일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌다고 명시하고 있습니다.

Gilead Sciences (GILD) a divulgué une opération d'initié par la directrice commerciale Johanna Mercier. Le 15/10/2025, elle a vendu 3 000 actions ordinaires à 118,08 $ par action (code de transaction S). Après la vente, elle détenait directement 110 193 actions.

Le dépôt indique que la transaction a été réalisée conformément à un plan de trading Rule 10b5-1 adopté le 20 février 2025.

Gilead Sciences (GILD) gab eine Insider-Transaktion der Chief Commercial Officer Johanna Mercier bekannt. Am 15.10.2025 verkaufte sie 3.000 Stammaktien zu 118,08 USD je Aktie (Transaktionscode S). Nach dem Verkauf besaß sie direkt 110.193 Aktien.

Die Einreichung gibt an, dass der Handel gemäß einem am 20. Februar 2025 übernommenen Rule-10b5-1-Handelsplan erfolgt ist.

جلايد ساينسز (GILD) كشفت عن صفقة داخلية من قبل رئيسة التجارة جوهانا ميرسييه. في 15/10/2025، قامت ببيع 3,000 سهماً من الأسهم الشائعة بسعر 118.08 دولاراً للسهم الواحد (رمز الصفقة S). بعد البيع، امتلكت مباشرة 110,193 سهماً.

تنص الإيداع أن التداول تم وفقاً لخطة تداول Rule 10b5-1 التي اعتمدت في 20 فبراير 2025.

吉利德科学(GILD) 公布了首席商务官 Johanna Mercier 的内部人交易。2025年10月15日,她以每股118.08美元的价格出售了3,000股普通股(交易代码为 S)。交易后,她直接持有11,0193股。

该披露称,该交易是根据于2025年2月20日通过的Rule 10b5-1交易计划进行的。

Positive
  • None.
Negative
  • None.

Gilead Sciences (GILD) ha divulgato una operazione insider da parte della Chief Commercial Officer Johanna Mercier. Il 15/10/2025 ha venduto 3.000 azioni comuni a 118,08$ per azione (codice di transazione S). Dopo la vendita possedeva direttamente 110.193 azioni.

La dichiarazione indica che l'operazione è stata effettuata ai sensi di un piano di trading Rule 10b5-1 adottato il 20 febbraio 2025.

Gilead Sciences (GILD) divulgó una operación de insider por parte de la Directora Comercial Johanna Mercier. El 15/10/2025 vendió 3,000 acciones comunes a 118,08 dólares por acción (código de transacción S). Después de la venta, poseía directamente 110,193 acciones.

La declaración indica que la operación se realizó conforme a un plan de trading Rule 10b5-1 adoptado el 20 de febrero de 2025.

길리어드 사이언스(GILD) 최고 상무 이사인 조하나 메르시에가 내부자 거래를 공시했습니다. 2025년 10월 15일, 보통주 3,000주를 주당 118.08달러에 매도했습니다 (거래 코드 S). 매도 후 그녀는 직접 110,193주를 보유하게 되었습니다.

해당 공시는 거래가 2025년 2월 20일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌다고 명시하고 있습니다.

Gilead Sciences (GILD) a divulgué une opération d'initié par la directrice commerciale Johanna Mercier. Le 15/10/2025, elle a vendu 3 000 actions ordinaires à 118,08 $ par action (code de transaction S). Après la vente, elle détenait directement 110 193 actions.

Le dépôt indique que la transaction a été réalisée conformément à un plan de trading Rule 10b5-1 adopté le 20 février 2025.

Gilead Sciences (GILD) gab eine Insider-Transaktion der Chief Commercial Officer Johanna Mercier bekannt. Am 15.10.2025 verkaufte sie 3.000 Stammaktien zu 118,08 USD je Aktie (Transaktionscode S). Nach dem Verkauf besaß sie direkt 110.193 Aktien.

Die Einreichung gibt an, dass der Handel gemäß einem am 20. Februar 2025 übernommenen Rule-10b5-1-Handelsplan erfolgt ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mercier Johanna

(Last) (First) (Middle)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CA 94404

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 S(1) 3,000 D $118.08 110,193 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Remarks:
/s/ Edward S. Son by Power of Attorney for Johanna Mercier 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

146.23B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY